| __timestamp | Halozyme Therapeutics, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 72429000 |
| Thursday, January 1, 2015 | 40028000 | 78634000 |
| Friday, January 1, 2016 | 45853000 | 75374000 |
| Sunday, January 1, 2017 | 53816000 | 92157000 |
| Monday, January 1, 2018 | 60804000 | 93326000 |
| Tuesday, January 1, 2019 | 77252000 | 103132000 |
| Wednesday, January 1, 2020 | 45736000 | 110171000 |
| Friday, January 1, 2021 | 50323000 | 218817000 |
| Saturday, January 1, 2022 | 143526000 | 233827000 |
| Sunday, January 1, 2023 | 149182000 | 267194000 |
| Monday, January 1, 2024 | 154335000 |
Unleashing insights
In the competitive world of biotechnology, managing operational costs is crucial for success. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Halozyme Therapeutics, Inc. and Lantheus Holdings, Inc. from 2014 to 2023. Over this period, Lantheus Holdings consistently outpaced Halozyme in SG&A spending, with a notable 270% increase from 2014 to 2023. Halozyme, while more conservative, saw a significant 315% rise in the same timeframe.
These trends highlight the strategic investments in administrative capabilities and market expansion, reflecting each company's growth trajectory and market positioning.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Lantheus Holdings, Inc.
Genmab A/S and Lantheus Holdings, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Analyzing R&D Budgets: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
Halozyme Therapeutics, Inc. vs Mesoblast Limited: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated